Taichu Biology

Innovative Drug Non Clinical
Research and Service Platform (CRO)

Taichu Biology, founded in October 2020, is a contract research organization (CRO) focusing on non clinical research and services of
innovative drugs, located in Life Blue Bay of Shanghai Lingang Special Area.

Business scope

Early screening of drugs

Early screening of drugs

In vivo (in vitro) drug effectiveness screening, including enzyme, cell, organ, tissue and animal level

Based on early pharmacokinetic screening, using ELISA, LC/MS, HPLC and other methods to screen the bioavailability and metabolic properties of early compounds

Early toxicity screening, including high-throughput genetic toxicity, cardiac toxicity, and carcinogenicity screening, etc
Pharmacodynamic research

Pharmacodynamic research

In vitro drug efficacy testing, including cell proliferation, antiviral, antibacterial, target binding, mechanism of action exploration, etc

In vivo efficacy evaluation, covering various animal models such as infection, tumors, immunity, central nervous system, respiration, cardiovascular system, liver, metabolic diseases, etc
Pharmacokinetics study

Pharmacokinetics study

Absorption, distribution, metabolism, excretion

Small molecule drug analysis and pharmacokinetics platform

Macromolecule drug analysis and pharmacokinetics platform
Non-clinical safety evaluation

Non-clinical safety evaluation

Single/multiple dose toxicity test

Safety pharmacology test

Local Toxicity Test

Genetic toxicity test

Reproductive toxicity test

Carcinogenicity test

Toxicokinetic detection

Immunogenicity testing

Team experience

The core management team is led by well-known domestic scientists, with over 30 years of experience in pharmacology and toxicology services, strong technical development capabilities, and professional experimental protocol design capabilities

30Many years

The team has over 30 years of experience in pharmacological and toxicological services
630Many

Serving over 630 new drug research and development institutions
8000Multiple

Completed over 8000 services
1200Multiple

Completed over 1200 new drug efficacy, pharmacokinetics, and safety evaluations
120Multiple

More than 120 projects have been declared and successfully conducted clinical trials in countries such as the US FDA, the Netherlands, Poland, and Australia.

Project experience

Experience in preclinical pharmacodynamics research

Organ like research:Successfully constructed 14 PDO models, covering major pathological models such as HGSC, EMC, CCC, SBT, etc

Bone system efficacy test:Models of osteoporosis, osteoarthritis, rheumatoid arthritis, etc

Screening and evaluation of analgesic drugs:Models of inflammatory pain, neuropathic pain, bone cancer pain, incision pain, etc

Screening and evaluation of hair care drugs:Models of androgenic alopecia and alopecia areata

Tumor efficacy test:Liver cancer, lung cancer, kidney cancer, breast cancer, ovarian cancer, gastric cancer, lymphoma, melanoma, glioma and other models

Cardiovascular and cerebrovascular efficacy test:Ischemic stroke, myocardial ischemia, hypertension, arrhythmia, hyperlipidemia/atherosclerosis and other models

Neuropsychiatric efficacy test:Alzheimer's disease, Parkinson's disease, epilepsy, spinal cord/brain injury, cerebral vasospasm, depression and other models

Efficacy test of COVID-19 neutralizing antibody

RSV neutralizing antibody titer detection test

Pharmacodynamic studies on mesenchymal stem cells in the treatment of ischemic stroke, ankylosing spondylitis, aGVHD, and other conditions
Experience in preclinical toxicology research

Toxicological evaluation research covering small molecule drugs, antibody drugs, ADC drugs, peptide protein drugs, small nuclear acid drugs, and cell gene therapy products.